PhaseRx, Inc.

PZRXQ

US71723F1030

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:42:58 21/09/2023 BST			5-day change	1st Jan Change
0.0002 ^USD	-.--%		-.--%	-.--%

2019	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
2018	PhaseRx, Inc. Bankruptcy Case Dismissed	CI

PhaseRx Seeks Corporate Restructuring And Alternatives

October 13, 2017 at 05:00 am

PhaseRx, Inc. (NasdaqCM:PZRX) is seeking corporate restructuring and review of strategic alternatives

Latest news about PhaseRx, Inc.

Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	30/01/19	CI
PhaseRx, Inc. Bankruptcy Case Dismissed	23/03/18	CI
Motion for Case Dismissal Filed for PhaseRx, Inc.	07/03/18	CI
Motion for De Minimis Asset Sale Approved for PhaseRx, Inc.	20/02/18	CI
PhaseRx, Inc.(OTCPK:PZRX.Q) dropped from NASDAQ Composite Index	02/02/18	CI
Motion for Asset Sale Approved for PhaseRx, Inc.	01/02/18	CI
Roivant Sciences GmbH entered into an asset purchase agreement to acquire substantially all of the assets from PhaseRx, Inc. for $6.8 million.	31/01/18	CI
Bidding Procedure Approved for PhaseRx, Inc.	27/12/17	CI
PhaseRx Considers Multiple Alternatives	14/12/17	CI
PhaseRx, Inc.(NasdaqCM:PZRX) dropped from S&P TMI Index	13/12/17	CI
PhaseRx, Inc. Filed for Bankruptcy	11/12/17	CI
Motion for Asset Sale Filed by PhaseRx, Inc.	11/12/17	CI
PhaseRx, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	09/11/17	CI
Phaserx, Inc. Announces Termination of Michael Houston as Chief Scientific Officer	13/10/17	CI
PhaseRx, Inc. Announces Reduction of Workforce by 10 Employees	13/10/17	CI
PhaseRx Seeks Corporate Restructuring And Alternatives	13/10/17	CI
Phaserx To Cut Half Its Workforce, Looks Into Potential Merger	13/10/17	CI
PhaseRx, Inc. Appoints Robert W. Overell as Principal Accounting Officer	26/09/17	CI
PhaseRx, Inc. Announces Resignation of Shing-Yin Tsui as Senior Vice President, Finance, Secretary and Principal Accounting Officer, Effective as of September 15, 2017	08/09/17	CI
Phaserx Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2017	10/08/17	CI
PhaseRx, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	11/05/17	CI
PhaseRx, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	27/03/17	CI
Certain Preferred Stock of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	13/11/16	CI
Certain Warrants of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	13/11/16	CI
Certain Stock Options of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	13/11/16	CI

Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHASERX, INC.	-.--%	2.34K
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs

PhaseRx, Inc.

Equities

PZRXQ

US71723F1030

Biotechnology & Medical Research

PhaseRx Seeks Corporate Restructuring And Alternatives

Latest news about PhaseRx, Inc.

Chart PhaseRx, Inc.

Company Profile

Sector Bio Therapeutic Drugs